NCT06649864View on ClinicalTrials.gov

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Liver Transplant; ComplicationsLiver Diseases
Interventions
DRUG

Autologous adipose derived mesenchymal stromal cells (AMSC)

Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER